HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Aurinia Pharmaceuticals, maintaining a price target of $13.
September 06, 2024 | 9:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Aurinia Pharmaceuticals, maintaining a price target of $13.
The reiteration of a Buy rating and maintenance of a $13 price target by HC Wainwright & Co. is a positive signal for Aurinia Pharmaceuticals. This suggests confidence in the company's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100